Loading…
Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ≤100 Cells/μL Who Start HIV Therapy in Resource-Limited Settings
Background. Cryptococcal meningitis (CM) remains a common AIDS-defining illness in Africa and Asia. Subclinical cryptococcal antigenemia is frequently unmasked with antiretroviral therapy (ART). We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify per...
Saved in:
Published in: | Clinical infectious diseases 2010-08, Vol.51 (4), p.448-455 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c2863-bdc025f477826f1b2ccf2f0f6883e2f4692e1ed8f3de0e1416bcfdec393e64a83 |
---|---|
cites | |
container_end_page | 455 |
container_issue | 4 |
container_start_page | 448 |
container_title | Clinical infectious diseases |
container_volume | 51 |
creator | Meya, David B. Manabe, Yukari C. Castelnuovo, Barbara Cook, Bethany A. Elbireer, Ali M. Kambugu, Andrew Kamya, Moses R. Bohjanen, Paul R. Boulware, David R. |
description | Background. Cryptococcal meningitis (CM) remains a common AIDS-defining illness in Africa and Asia. Subclinical cryptococcal antigenemia is frequently unmasked with antiretroviral therapy (ART). We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify persons with subclinical cryptococcosis and the efficacy of preemptive fluconazole therapy. Methods. There were 609 ART-naive adults with AIDS who started ART in Kampala, Uganda, and who had a serum CRAG prospectively measured during 2004–2006. The number needed to test and treat with a positive CRAG was assessed for ≥30-month outcomes. Results. In the overall cohort, 50 persons (8.2%) were serum CRAG positive when starting ART. Of 295 people with a CD4+ cell count ≤100 cells/μL and without prior CM, 26 (8.8%; 95% confidence interval [CI], 5.8%–12.6%) were CRAG positive, of whom 21 were promptly treated with fluconazole (200–400 mg) for 2–4 weeks. Clinical CM developed in 3 fluconazole-treated persons, and 30-month survival was 71% (95% CI, 48%–89%). In the 5 CRAG-positive persons with a CD4+ cell count ≤100 cells/μL treated with ART but not fluconazole, all died within 2 months of ART initiation. The number needed to test and treat with CRAG screening and fluconazole to prevent 1 CM case is 11.3 (95% CI, 7.9–17.1) at costs of $190 (95% CI, $132–$287). The number needed to test and treat to save 1 life is 15.9 (95% CI, 11.1–24.0) at costs of $266 (95% CI, $185–$402). The cost per disability-adjusted life year saved is $21 (95% CI, $15–$32). Conclusions. Integrating CRAG screening into HIV care, specifically targeting people with severe immunosuppression (CD4+ cell count ≤100 cells/μL) should be implemented in treatment programs in resource-limited settings. ART alone is insufficient treatment for CRAG-positive persons. |
doi_str_mv | 10.1086/655143 |
format | article |
fullrecord | <record><control><sourceid>jstor_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1086_655143</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>20750788</jstor_id><oup_id>10.1086/655143</oup_id><sourcerecordid>20750788</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2863-bdc025f477826f1b2ccf2f0f6883e2f4692e1ed8f3de0e1416bcfdec393e64a83</originalsourceid><addsrcrecordid>eNp1kMFu1DAQhiMEEqXAGyANB7igUDuOHedYpYVdKUBFCkW9RF5n3HXZjSPbC-wj8B48BicegIfgSUgIKidOM5r55tPoT5KHlDynRIojwTnN2a3kgHJWpIKX9PbYEy7TXDJ5N7kXwjUhlErCD5IflQsxPTUGdbSfsMcQwBlo0O-2UPn9EJ12WqsNHPfRXmEPjfaIve2vIDo48zgeRThBFdcB1NaN88XyfbrsJyN2cIY-uD7AZxvXoKA6yZ9BhZsNVG43Hv76-o0S8mcSjn5-r-Fi7aCJysdJA-dr9GrYg-3hLQa38xrT2m7tZG4wxvGNcD-5Y9Qm4IO_9TB59-L0vFqk9ZuXy-q4TnUmBUtXnSYZN3lRyEwYusq0NpkhRkjJMDO5KDOk2EnDOiRIcypW2nSoWclQ5Eqyw-Tp7NXeheDRtIO3W-X3LSXtlHw7Jz-CT2ZwUGFMznjVaxtu6IyRspS8GLnHM-d2w_9dj2bmOkTn_zlIwUkhp6fSeW9DxC83e-U_tqJgBW8XHy7by8XrUl68qtuG_QZqLqit</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ≤100 Cells/μL Who Start HIV Therapy in Resource-Limited Settings</title><source>JSTOR Archival Journals and Primary Sources Collection【Remote access available】</source><source>Oxford Journals Online</source><creator>Meya, David B. ; Manabe, Yukari C. ; Castelnuovo, Barbara ; Cook, Bethany A. ; Elbireer, Ali M. ; Kambugu, Andrew ; Kamya, Moses R. ; Bohjanen, Paul R. ; Boulware, David R.</creator><creatorcontrib>Meya, David B. ; Manabe, Yukari C. ; Castelnuovo, Barbara ; Cook, Bethany A. ; Elbireer, Ali M. ; Kambugu, Andrew ; Kamya, Moses R. ; Bohjanen, Paul R. ; Boulware, David R.</creatorcontrib><description>Background. Cryptococcal meningitis (CM) remains a common AIDS-defining illness in Africa and Asia. Subclinical cryptococcal antigenemia is frequently unmasked with antiretroviral therapy (ART). We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify persons with subclinical cryptococcosis and the efficacy of preemptive fluconazole therapy. Methods. There were 609 ART-naive adults with AIDS who started ART in Kampala, Uganda, and who had a serum CRAG prospectively measured during 2004–2006. The number needed to test and treat with a positive CRAG was assessed for ≥30-month outcomes. Results. In the overall cohort, 50 persons (8.2%) were serum CRAG positive when starting ART. Of 295 people with a CD4+ cell count ≤100 cells/μL and without prior CM, 26 (8.8%; 95% confidence interval [CI], 5.8%–12.6%) were CRAG positive, of whom 21 were promptly treated with fluconazole (200–400 mg) for 2–4 weeks. Clinical CM developed in 3 fluconazole-treated persons, and 30-month survival was 71% (95% CI, 48%–89%). In the 5 CRAG-positive persons with a CD4+ cell count ≤100 cells/μL treated with ART but not fluconazole, all died within 2 months of ART initiation. The number needed to test and treat with CRAG screening and fluconazole to prevent 1 CM case is 11.3 (95% CI, 7.9–17.1) at costs of $190 (95% CI, $132–$287). The number needed to test and treat to save 1 life is 15.9 (95% CI, 11.1–24.0) at costs of $266 (95% CI, $185–$402). The cost per disability-adjusted life year saved is $21 (95% CI, $15–$32). Conclusions. Integrating CRAG screening into HIV care, specifically targeting people with severe immunosuppression (CD4+ cell count ≤100 cells/μL) should be implemented in treatment programs in resource-limited settings. ART alone is insufficient treatment for CRAG-positive persons.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/655143</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Oxford: The University of Chicago Press</publisher><subject>AIDS ; Antigens ; Antiretrovirals ; Biological and medical sciences ; Cost control ; Cost estimates ; Cryptococcal meningitis ; Fixed costs ; HIV ; HIV/AIDS ; Human mycoses ; Human viral diseases ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infectious diseases ; Medical sciences ; Miscellaneous mycoses ; Mortality ; Mycoses ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>Clinical infectious diseases, 2010-08, Vol.51 (4), p.448-455</ispartof><rights>2010 Infectious Diseases Society of America</rights><rights>2010 by the Infectious Diseases Society of America 2010</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2863-bdc025f477826f1b2ccf2f0f6883e2f4692e1ed8f3de0e1416bcfdec393e64a83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/20750788$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/20750788$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,58593,58826</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23099857$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Meya, David B.</creatorcontrib><creatorcontrib>Manabe, Yukari C.</creatorcontrib><creatorcontrib>Castelnuovo, Barbara</creatorcontrib><creatorcontrib>Cook, Bethany A.</creatorcontrib><creatorcontrib>Elbireer, Ali M.</creatorcontrib><creatorcontrib>Kambugu, Andrew</creatorcontrib><creatorcontrib>Kamya, Moses R.</creatorcontrib><creatorcontrib>Bohjanen, Paul R.</creatorcontrib><creatorcontrib>Boulware, David R.</creatorcontrib><title>Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ≤100 Cells/μL Who Start HIV Therapy in Resource-Limited Settings</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><addtitle>Clinical Infectious Diseases</addtitle><description>Background. Cryptococcal meningitis (CM) remains a common AIDS-defining illness in Africa and Asia. Subclinical cryptococcal antigenemia is frequently unmasked with antiretroviral therapy (ART). We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify persons with subclinical cryptococcosis and the efficacy of preemptive fluconazole therapy. Methods. There were 609 ART-naive adults with AIDS who started ART in Kampala, Uganda, and who had a serum CRAG prospectively measured during 2004–2006. The number needed to test and treat with a positive CRAG was assessed for ≥30-month outcomes. Results. In the overall cohort, 50 persons (8.2%) were serum CRAG positive when starting ART. Of 295 people with a CD4+ cell count ≤100 cells/μL and without prior CM, 26 (8.8%; 95% confidence interval [CI], 5.8%–12.6%) were CRAG positive, of whom 21 were promptly treated with fluconazole (200–400 mg) for 2–4 weeks. Clinical CM developed in 3 fluconazole-treated persons, and 30-month survival was 71% (95% CI, 48%–89%). In the 5 CRAG-positive persons with a CD4+ cell count ≤100 cells/μL treated with ART but not fluconazole, all died within 2 months of ART initiation. The number needed to test and treat with CRAG screening and fluconazole to prevent 1 CM case is 11.3 (95% CI, 7.9–17.1) at costs of $190 (95% CI, $132–$287). The number needed to test and treat to save 1 life is 15.9 (95% CI, 11.1–24.0) at costs of $266 (95% CI, $185–$402). The cost per disability-adjusted life year saved is $21 (95% CI, $15–$32). Conclusions. Integrating CRAG screening into HIV care, specifically targeting people with severe immunosuppression (CD4+ cell count ≤100 cells/μL) should be implemented in treatment programs in resource-limited settings. ART alone is insufficient treatment for CRAG-positive persons.</description><subject>AIDS</subject><subject>Antigens</subject><subject>Antiretrovirals</subject><subject>Biological and medical sciences</subject><subject>Cost control</subject><subject>Cost estimates</subject><subject>Cryptococcal meningitis</subject><subject>Fixed costs</subject><subject>HIV</subject><subject>HIV/AIDS</subject><subject>Human mycoses</subject><subject>Human viral diseases</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Miscellaneous mycoses</subject><subject>Mortality</subject><subject>Mycoses</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNp1kMFu1DAQhiMEEqXAGyANB7igUDuOHedYpYVdKUBFCkW9RF5n3HXZjSPbC-wj8B48BicegIfgSUgIKidOM5r55tPoT5KHlDynRIojwTnN2a3kgHJWpIKX9PbYEy7TXDJ5N7kXwjUhlErCD5IflQsxPTUGdbSfsMcQwBlo0O-2UPn9EJ12WqsNHPfRXmEPjfaIve2vIDo48zgeRThBFdcB1NaN88XyfbrsJyN2cIY-uD7AZxvXoKA6yZ9BhZsNVG43Hv76-o0S8mcSjn5-r-Fi7aCJysdJA-dr9GrYg-3hLQa38xrT2m7tZG4wxvGNcD-5Y9Qm4IO_9TB59-L0vFqk9ZuXy-q4TnUmBUtXnSYZN3lRyEwYusq0NpkhRkjJMDO5KDOk2EnDOiRIcypW2nSoWclQ5Eqyw-Tp7NXeheDRtIO3W-X3LSXtlHw7Jz-CT2ZwUGFMznjVaxtu6IyRspS8GLnHM-d2w_9dj2bmOkTn_zlIwUkhp6fSeW9DxC83e-U_tqJgBW8XHy7by8XrUl68qtuG_QZqLqit</recordid><startdate>20100815</startdate><enddate>20100815</enddate><creator>Meya, David B.</creator><creator>Manabe, Yukari C.</creator><creator>Castelnuovo, Barbara</creator><creator>Cook, Bethany A.</creator><creator>Elbireer, Ali M.</creator><creator>Kambugu, Andrew</creator><creator>Kamya, Moses R.</creator><creator>Bohjanen, Paul R.</creator><creator>Boulware, David R.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20100815</creationdate><title>Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ≤100 Cells/μL Who Start HIV Therapy in Resource-Limited Settings</title><author>Meya, David B. ; Manabe, Yukari C. ; Castelnuovo, Barbara ; Cook, Bethany A. ; Elbireer, Ali M. ; Kambugu, Andrew ; Kamya, Moses R. ; Bohjanen, Paul R. ; Boulware, David R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2863-bdc025f477826f1b2ccf2f0f6883e2f4692e1ed8f3de0e1416bcfdec393e64a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>AIDS</topic><topic>Antigens</topic><topic>Antiretrovirals</topic><topic>Biological and medical sciences</topic><topic>Cost control</topic><topic>Cost estimates</topic><topic>Cryptococcal meningitis</topic><topic>Fixed costs</topic><topic>HIV</topic><topic>HIV/AIDS</topic><topic>Human mycoses</topic><topic>Human viral diseases</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Miscellaneous mycoses</topic><topic>Mortality</topic><topic>Mycoses</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meya, David B.</creatorcontrib><creatorcontrib>Manabe, Yukari C.</creatorcontrib><creatorcontrib>Castelnuovo, Barbara</creatorcontrib><creatorcontrib>Cook, Bethany A.</creatorcontrib><creatorcontrib>Elbireer, Ali M.</creatorcontrib><creatorcontrib>Kambugu, Andrew</creatorcontrib><creatorcontrib>Kamya, Moses R.</creatorcontrib><creatorcontrib>Bohjanen, Paul R.</creatorcontrib><creatorcontrib>Boulware, David R.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>CrossRef</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meya, David B.</au><au>Manabe, Yukari C.</au><au>Castelnuovo, Barbara</au><au>Cook, Bethany A.</au><au>Elbireer, Ali M.</au><au>Kambugu, Andrew</au><au>Kamya, Moses R.</au><au>Bohjanen, Paul R.</au><au>Boulware, David R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ≤100 Cells/μL Who Start HIV Therapy in Resource-Limited Settings</atitle><jtitle>Clinical infectious diseases</jtitle><stitle>Clinical Infectious Diseases</stitle><addtitle>Clinical Infectious Diseases</addtitle><date>2010-08-15</date><risdate>2010</risdate><volume>51</volume><issue>4</issue><spage>448</spage><epage>455</epage><pages>448-455</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><notes>istex:8FC3B44C924F247B960E6DD97B05A2D43AA80786</notes><notes>ark:/67375/HXZ-ZHN98WML-S</notes><abstract>Background. Cryptococcal meningitis (CM) remains a common AIDS-defining illness in Africa and Asia. Subclinical cryptococcal antigenemia is frequently unmasked with antiretroviral therapy (ART). We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify persons with subclinical cryptococcosis and the efficacy of preemptive fluconazole therapy. Methods. There were 609 ART-naive adults with AIDS who started ART in Kampala, Uganda, and who had a serum CRAG prospectively measured during 2004–2006. The number needed to test and treat with a positive CRAG was assessed for ≥30-month outcomes. Results. In the overall cohort, 50 persons (8.2%) were serum CRAG positive when starting ART. Of 295 people with a CD4+ cell count ≤100 cells/μL and without prior CM, 26 (8.8%; 95% confidence interval [CI], 5.8%–12.6%) were CRAG positive, of whom 21 were promptly treated with fluconazole (200–400 mg) for 2–4 weeks. Clinical CM developed in 3 fluconazole-treated persons, and 30-month survival was 71% (95% CI, 48%–89%). In the 5 CRAG-positive persons with a CD4+ cell count ≤100 cells/μL treated with ART but not fluconazole, all died within 2 months of ART initiation. The number needed to test and treat with CRAG screening and fluconazole to prevent 1 CM case is 11.3 (95% CI, 7.9–17.1) at costs of $190 (95% CI, $132–$287). The number needed to test and treat to save 1 life is 15.9 (95% CI, 11.1–24.0) at costs of $266 (95% CI, $185–$402). The cost per disability-adjusted life year saved is $21 (95% CI, $15–$32). Conclusions. Integrating CRAG screening into HIV care, specifically targeting people with severe immunosuppression (CD4+ cell count ≤100 cells/μL) should be implemented in treatment programs in resource-limited settings. ART alone is insufficient treatment for CRAG-positive persons.</abstract><cop>Oxford</cop><pub>The University of Chicago Press</pub><doi>10.1086/655143</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1058-4838 |
ispartof | Clinical infectious diseases, 2010-08, Vol.51 (4), p.448-455 |
issn | 1058-4838 1537-6591 |
language | eng |
recordid | cdi_crossref_primary_10_1086_655143 |
source | JSTOR Archival Journals and Primary Sources Collection【Remote access available】; Oxford Journals Online |
subjects | AIDS Antigens Antiretrovirals Biological and medical sciences Cost control Cost estimates Cryptococcal meningitis Fixed costs HIV HIV/AIDS Human mycoses Human viral diseases Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Medical sciences Miscellaneous mycoses Mortality Mycoses Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
title | Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ≤100 Cells/μL Who Start HIV Therapy in Resource-Limited Settings |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T03%3A21%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-Effectiveness%20of%20Serum%20Cryptococcal%20Antigen%20Screening%20to%20Prevent%20Deaths%20among%20HIV-Infected%20Persons%20with%20a%20CD4+%20Cell%20Count%20%E2%89%A4100%20Cells/%CE%BCL%20Who%20Start%20HIV%20Therapy%20in%20Resource-Limited%20Settings&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Meya,%20David%20B.&rft.date=2010-08-15&rft.volume=51&rft.issue=4&rft.spage=448&rft.epage=455&rft.pages=448-455&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/655143&rft_dat=%3Cjstor_cross%3E20750788%3C/jstor_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2863-bdc025f477826f1b2ccf2f0f6883e2f4692e1ed8f3de0e1416bcfdec393e64a83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_jstor_id=20750788&rft_oup_id=10.1086/655143&rfr_iscdi=true |